Back

CTEC

0.23%
NEUTRAL

ConvaTec Responds to LCD Postponement in US

Why we think this is neutral

This RNS announcement is a general update on the postponement of Local Coverage Determinations (LCDs) for skin substitute products in the US. While this news is positive for ConvaTec's InnovaMatrix product, the announcement does not contain any mandatory news types such as contract news, order news, or financial figures. Therefore, the sentiment is assessed as neutral.

Key Points

  • ConvaTec welcomes the postponement of LCDs for skin substitute products in the US
  • This will allow continued access to ConvaTec's InnovaMatrix® product for Medicare patients
  • ConvaTec is conducting randomised controlled trials for InnovaMatrix® in DFU and VLU, expected to report in 2026

Summary

The healthcare company welcomes the postponement of LCDs in the US, which will allow continued access to its InnovaMatrix product for Medicare patients.

ConvaTec welcomes the postponement by the Centers for Medicare & Medicaid Services (CMS) of the LCDs for Skin Substitute Grafts/Cellular and Tissue-Based Products for the treatment of Diabetic Foot Ulcers (DFUs) and Venous Leg Ulcers (VLUs). This means that Medicare patients will continue to benefit from access to ConvaTec's InnovaMatrix® product. ConvaTec remains committed to evidence-based medicine and is conducting randomised controlled trials for InnovaMatrix® in DFU and VLU, which are expected to report in 2026.

Key Dates

2026
Randomised controlled trials for InnovaMatrix® in DFU and VLU expected to report
GENERAL UPDATE